Lonza paper reveals secrets behind cGMP stem cell production

By Dan Stanton contact

- Last updated on GMT

Lonza paper reveals secrets behind cGMP stem cell production

Related tags: Pluripotent stem cells, Stem cell

Lonza has published a guide to clinical-grade induced pluripotent stem cell (IPSC) manufacture, addressing concerns around the derivation of cellular materials.

Ever wanted to know how to manufacture stem cells under cGMP-compliant conditions? Well, contract manufacturing organisation (CMO) Lonza has published an A-Z guide to producing clinical-grade iPSCs in the Stem Cell Reports Journal​.

Entitled ‘cGMP-Manufactured Human Induced Pluripotent Stem Cells Are Available for Pre-clinical and Clinical Applications,’ the paper details Lonza’s processing flow from defining tissue requirements to the characterisation and viral testing of stem cells made at its Walkersville, Maryland facility.

“iPSC MCBs [master cell banks] have to be generated using a robust, reproducible, and cGMP-compliant manufacturing process, applying best practices for cell culture, documentation, and quality control,”​ the authors state.

Lonza’s iPSCs use CD34+ cells from a fresh umbilical cord blood unit.

“Sourcing from cord blood when using an optimized and reproducible integration-free method allows one to develop a bank of well characterized and tested pluripotent cells that can be used for differentiation into clinically relevant cells.”

Lonza stem cell manufacturing co Stem Cell Reports DOI 10.1016j.stemcr.2015.08.015
c/o Stem Cell Reports DOI 10.1016j.stemcr

Procuring raw materials

But while the CMO offers a step-by-step guideline, it warns that this alone “will not be sufficient to ensure clinically relevant products, nor will adding certification or training complete the process,”​ in appeasing regulators.

An iPSC manufacturer must conform to regulations surrounding the procurement of human donor tissue, while control material must be developed to generate convincing data on in-process testing, lot-to-lot variability, and release assays - themselves needing to be developed and validated.

“There were three levels of concerns we had to address during the derivation process,”​ the firm says, the first asking: “Was the process of obtaining tissue compliant with the new guidance provided by the FDA​ and compatible with the final donor consent rule?”

“The second issue was keeping a backup tissue sample and multiple clones of iPSC lines from the same donor.”​ Lonza opted against this for its first line it generated, but said for the actual therapy, each group will prefer generating its own lines.

“We expect, however, that, if they opt to use the described process and SOPs, then their cost will be significantly lower, and that the FDA will accept much of the pre-clinical data that have been generated with this line.”

Related news

Show more

Related products

show more

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Related suppliers

Follow us

Products

View more

Webinars